|Numéro de publication||US3249109 A|
|Type de publication||Octroi|
|Date de publication||3 mai 1966|
|Date de dépôt||1 nov. 1963|
|Date de priorité||1 nov. 1963|
|Numéro de publication||US 3249109 A, US 3249109A, US-A-3249109, US3249109 A, US3249109A|
|Inventeurs||Maeth Harry, Pennings Ralph David|
|Cessionnaire d'origine||Maeth Harry, Pennings Ralph David|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Citations de brevets (9), Référencé par (132), Classifications (24)|
|Liens externes: USPTO, Cession USPTO, Espacenet|
Ma 3, 1966 H. MAETH ETAL 3,249,109
TORI CAL DRESS ING Filed Nov. 1, 1963 HARRY MA ETH R. DAVID PENNINGS BY Vndrus 9f Star/ 52 A'f-ronwsvs INVENTORS United States Patent 3,249,109 TOPICAL DRESSING Harry Maeth, 101 Main, and Ralph David Pennings, 302 Main, both of Mosinee, Wis. Filed Nov. 1, 1963, Ser. No. 320,809 9 Claims. (Cl. 128-268) This invention relates to a pharmaceutical preparation and more particularly to a pharmaceutical preparation for topical application to mucous membranes.
It is often desired to apply a dressing to the mucous membranes of the body, such as the oral cavity. For example, it may be desired to apply a post-operative dressing following gum surgery, or to use a dressing for intraoral traumatic wounds. In the past, dressings to be used in the oral cavity were generally made of tinfoil and included a base plate material which required heat to adapt it to its position on the membrane. If the dessing included a medicament or therapeutic agent, leakage of the agent generally occurred and could not be controlled. This resulted in the incomplete application of the agent to the site of treatment and dispersion of the agent into the mouth and possible entry into the alimentary tract.
The present invention is directed to an adhesive dressing to be topically applied to the body and in particular to the mucous membranes, such as the oral cavity. More specifically, the dressing or pharmaceutical preparation includes a flexible adhesive base composed of hydrated gelatin and including a small amount of pectin. In addition, a medicament or therapeutic agent can be incorporated in the flexible base. The base material is applied to the membrane at the site of the treatment and will adhere to the moist membrane. To prevent loss of the medicament or therapeutic agent, a backing member is applied to the outer surface of the flexible base. The backing member may take the form of a generally inert fabric, such as glass fibers, muslin or the like.
The hydrated gelatin base, which serves as the vehicle for the medicament or therapeutic agent, is flexible and is very adhesive and will readily adhere to the surfaces of the oral cavity or other mucous membranes. The gelatin base will remain flexible for extended periods of time and will not crack or chip. Moreover, the base does not contain oils or essential oils which can be irritating or toxic to the patient.
The use of the fabric backing layer insures theproper dosage of the medicament or therapeutic agent and prevents the dispersion of the agent from the site of treatment, thereby preventing the dispersion of the agent into the mouth and possible entry into the alimentary tract.
The pharmaceutical preparation or dressing can be used as a post-operative dressing in gum surgery, as a dressing for intraoral traumatic wounds, for the management of soft tissue lesions in the mouth, and as an irradiation shield for the treatment of malignant conditions with X-ray. In addition, it can also be used for topical application to the skin for abrasions, burns, varicose ulcers, and the like.
Other objects and advantages will appear in the course of the following description.
The drawings illustrate the best mode presently contemplated of carrying out the invention.
In the drawings:
FIG. 1 is a perspective view of a dressing prepared in accordance with the invention;
I FIG. 2 is a modified form of the invention showing the dressing in the form of a roll; and
FIG. 3 is a second modified form of the invention showing the dress-ing in the form of a pre-cut strip.
3,249,109 Patented May 3 1966 FIG. 1 shows a dressing 1 to be used for topical applications and particularly to the mucous membranes of the body. The dressing has particular application to the mucous membranes of the oral cavity, but also includes other areas such as the vagina, rectum, etc.
The dressing 1 includes a flexible hydrated gelatin base 2 and a fabric backing member 3. The hydrated gelatin base 2 contains by weight, 10 to 40% gelatin, 5 to Water, 15 to 80% polyhydric alcohol and up to 15% pectin.
The preferred range of composition, in weight percent is as follows:
Percent Gelatin 1033 Water 50-85 Polyhydric alcohol 15-35 Pectin 1-4 The hydrated gelatin gives the base its consistency and bulk and serves as the vehicle for the incorporation of medicaments and therapeutic agents.
Pectin is a carbohydrate obtained from the dilute acid extract of the inner portion of the rind of citrus fruits or apple peel. Pectin consists chiefly of partially methoxylated polygalacturonic acids.
The pectin provides adhesive properties to the hydrated gelatin and enables the gelatin base to be readily applied to moist surfaces, such as the mucous membranes.
The polyhydric alcohol serves to prevent brittleness and retains the flexible characteristics of the material for extended periods. The polyhdric alcohol can be glycerin, polyoxyethylene, propylene glycol, sorbitol, ethylene glycol (when used externally), and the like.
It is also contemplated that the base 2 will include a pharmacologically active material such as a medicament or a therapeutic agent. More specifically, the pharmacologically active material may include enzymes such as hyaluronidase; vasoconstrictors such as epinephrine; bactericides; bacteristatics; antacids; anesthetics; corticosteroids; antibiotics; hemostats; fluorides such as sodium fluoride, stannous fluoride, calcium fluoride; astringents, hormones; vitamins; tissue growth promoters such as Peruvian balsam; deodorants such as charcoal, and chlorophyll, and the like. The pharmacologically active material is used in an amount up to 10% by weight of the composition with the particular amount depending on the activity of the material.
The backing member 3 is formed of an inert, non toxic fibrous material such as glass fiber, muslin and the like. The use of glass fiber cloth has proven particularly satisfactory as a reinforcement and as a dam to reduce the spreading of the pharmacologically active material bility and a marked resistance to steam, corrosive fumes and most acids. In addition, the glass fiber will not absorb water and can be readily sterilized and re-sterilized and withstands repeated folding and creasing.
The fabric backing member 3 serves as a barrier and assures that the proper dosage of the medicament or therapeutic agent is supplied to the site to be treated. The backing member 3 prevents the agent from being dispersed into the mouth and prevents the entry of the agent into the alimentary tract.
To prepare the dressing of the invention, the gelatin and a portion of the Water and glycerin are mixed at an elevated temperature of about C. to form a gelatin component. ing portion of the water and glycerin to form a pectin component which is then added to the heated gelatin component. In some cases it may be desirable to add a The pectin is then mixed with the remainsmall amount, in the range of 1 to 2% of the total composition weight, of alcohol, such as ethyl alcohol, to the pectin component. The alcohol provides a rapid hydration of the pectin and can be omitted, but, if omitted, increases the time required for preparation.
After adding the pectin component to the gelatin component, the medicament or therapeutic agent is added as a solution or suspension, depending upon the particular agent used. The entire composition is then agitated to thoroughly mix the components and is subsequently poured into the desired mold and cooled. The backing member 3 is then overlayed onto the base material.
Example 1 As a specific example of the preparation, 30 grams of gelatin, 30 cc. of distilled water and 30 cc. of glycerin were mixed together and heated to a temperature of 90 C. to melt the gelatin. After the gelatin was melted, the pectin component consisting of 5 cc. of ethyl alcohol, 40 cc. of distilled water, cc. of glycerin and 5 grams of pectin was added to the liquid gelatin component and mixed therewith.
After adding the pectin component, 8 grams of Benzocaine and 40 cc. of alcohol, and 0.5 gram of Triburon (triclobisonium chloride) in 10 cc. of distilled water were added to the composition. After mixing in the Benzocaine and Triburon, the composition was poured into a mold and cooled. A glass fiber backing sheet was then overlayed over the composition and pressed firmly therein.
The resulting dressing was flexible and very adhesive and could readily be applied to mucous membranes.
Example 2 Three grams of pectin, 10 cc. of ethyl alcohol, 80 cc. of distilled water and 40 cc. of glycerin were mixed together. Forty grams of gelatin were added to this mixture and the entire composition heated to a temperature of 90 to 100 C. to melt the gelatin. Subsequently, 0.25
gram of Triburon in 17 cc. of glycerin and 20 cc. of distilled water were added to the gelatin-pectin composition. The resulting composition was then poured onto a suitable mold and cooled.
FIG. 2 shows a modified form of the invention in which the dressing is in strip form. In this embodiment the dressing includes a hydrated gelatin base 4 similar in composition to gelatin base 2 of the first embodiment. A fabric backing member 5 is applied to one surface of the base 4 and the backing member 5 is similar in structure and function to the backing member 3 of the first embodiment. In addition, a protective strip of material, such as waxed paper or other material, is applied to the outer surface of the barrier and serves to prevent the strip from sticking to itself when it is wound in spiral form.
The strip shown in FIG. 2 can be unwound as desired and cut to any length, depending on the nature of the site to be treated.
FIG. 3 shows a second modified form of the invention in which the dressing is in the form of a pre-cut strip. In this embodiment, the hydrated gelatin base 7, similar to base 2 of the first embodiment, is applied to an adhesive backing member 8. In this embodiment, a protective strip of material is applied to the adhesive surface of the strip 8 and can be removed immediately prior to application of the strip to the body surface.
The dressing of the invention is used for topical application, and particularly to the moist mucous membranes. For example, the dressing can be used as a post-operative dressing following surgery, as a dressing for traumatic wounds, 'as a dressing for soft tissue lesions and it also may be employed as an irradiation shield for the treatment of malignant conditions with X-ray. In this lattercase, a radiation barrier, such as powdered lead or barium sulphate, can be incorporated in the flexible base 2 in an amount of about 10 to 30% by weight of the base. The lead or barium sulphate is radiopaque material and serves as an irradiation shield to protect structures such as teeth and soft tissues from the radiation. This type of barrier is considerably more flexible and pliable than sheet lead for intraoral use, and being a lightweight material, is exceedingly more comfortable to the patient.
The dressing of the invention is flexible and will tightly adhere to moist membrane surfaces. If the dressing is to be applied to the external body tissues, it may be necessary to moisten the tissue before application.
It is contemplated that pharmacologically active materials can be incorporated in the hydrated gelatin base and the backing member serves to concentrate the activity of the material at the site of treatment and prevents the pharmacologically active material from dispersing outwardly into the mouth or other regions of the body.
Various modes of carrying out the invention are contemplated as being within the scope of the following claims particularly pointing out and distinctly claiming the subject matter which is regarded as the invention.
1. A pressure sensitive dressing for topical application, comprising a solid, flexible hydrated gelatin base capable of maintaining its shape and containing a suflicient amount of pectin to provide initial adhesiveness for application to moist tissue and containing a sufiicient amount of a polyhydric alcohol to maintain flexibility for extended periods, and a generally inert non-toxic fibrous backing member disposed on one surface of said base and serving to prevent the outward dispersion of materials from the base.
2. A dressing for topical applications, comprising a solid, flexible, adhesive, film-like, hydrated gelatin base consisting essentially by weight of 10 to 40% gelatin, 5 to 85% water, 15 to of a polyhydric alcohol, and up to 15% pectin, and a fibrous backing member applied to one surface of the base, said backing member reinforcing the base and serving to prevent the outward dispersion of materials from the base.
3. The structure of claim 2, in which the hydrated gelatin base contains up to 10% by weight of a pharmacologically active material, said backing member serving to concentr-ate the pharmacologically active material at the site of treatment and preventing the outward dispersion of said material.
4. The structure of claim 2, in which the polyhydric alcohol is selected from the group consisting of glycerin, polyoxyethylene, propylene glycol, ethylene glycol, and sorbitol.
5. The structure of claim 3, in which the backing member is composed of glass fiber fabric.
6. A pressure sensitive dressing for topical applications, comprising a nonflow-able flexible, adhesive, hydrated gelatin sheet consisting essentially by weight of 10 to 33% gelatin, 50 to water, 1 to 4% pectin, 15 to 35% glycerin, and up to 10% of a pharmacologically active material, and a fabric backing member applied to one surface of the hydrated gelatin sheet, said backing member serving to concentrate the pharmacologically active material at the site of treatment and preventing the outward dispersion of said material.
7. The structure of claim 6 in which the hydrated gel-atin sheet also includes from 1 to 2% by weight of alcohol.
8. A dressing for topical applications, comprising a flexible, adhesive, hydrated gelatin base consisting essentially by weight of 10 to 40% gelatin, 5 to 85% Water, 15 to 80% of a polyhydric alcohol, up to 15% pectin and from 10 to 30% by weight of a material selected from the group consisting of lead and barium sulfate, and a fibrous backing member applied to one surface of the base, said backing member reinforcing the base and serving to prevent the outward dispersion of the material from the base, said material serving as a radiation shield to protect portions of the body from radiation.
9. A pressure sensitive article, comprising a flexible, adhesive, hydrated gelatin base containing up to 30% by weight of a radiopaque material, and a fabric backing member applied to one surface of the hydrated gelatin base, said backing member serving to concentrate the radiopaque material at the site of treatment and prevent the outward dispersion of said materiaL-said mtaerial serving as a radiation shield to protect portions of the article from radiation.
References Cited by the Examiner UNITED STATES PATENTS 307,537 11/1884 'Foulks 167 84 335,799 2/ 1886 Baby. 2,115,237 4/1938 Scholl 128268 X 6 Donaldson 1'28156 Shrontz 128-268 Reese.
Hirsch 106-125 Steinhardt 32--2 X FOREIGN PATENTS Germany.
OTHER REFERENCES Macleods Physiology in Modern Medicine, Bard, 8th edition, 1938.
ROBERT E. MORGAN, Primary Examiner.
15 RICHARD A. GAUDET, Examiner.
C. F. ROSENBAUM, Assistant Examiner.
|Brevet cité||Date de dépôt||Date de publication||Déposant||Titre|
|US307537 *||4 nov. 1884||Dental capsicum-bag|
|US335799 *||26 oct. 1885||9 févr. 1886||Itnesses|
|US2115237 *||11 mai 1936||26 avr. 1938||Scholl William M||Medicated button|
|US2450083 *||7 févr. 1944||28 sept. 1948||Munising Paper Company||Treated paper liner for adhesive rolls|
|US2501544 *||23 oct. 1946||21 mars 1950||Shellmar Products Corp||Therapeutic product|
|US2583341 *||21 mars 1950||22 janv. 1952||Reese John D||Skin graft receiving member|
|US2950980 *||10 sept. 1958||30 août 1960||Arthur Hirsch||Adhesive compositions|
|US3029187 *||20 févr. 1958||10 avr. 1962||Amos Steinhardt||Gelating adhesive pharmaceutical preparations|
|DE1074979B *||Titre non disponible|
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|US3329145 *||12 févr. 1965||4 juil. 1967||Johnson & Johnson||Sanitary napkin having control element with gel-forming material|
|US3339546 *||13 déc. 1963||5 sept. 1967||Squibb & Sons Inc||Bandage for adhering to moist surfaces|
|US3444858 *||11 mai 1966||20 mai 1969||Higham S Russell||Method and means for administering drugs|
|US3598123 *||1 avr. 1969||10 août 1971||Alza Corp||Bandage for administering drugs|
|US3688406 *||7 août 1970||5 sept. 1972||Frank W Hindsley||Apparatus for and method of applying decay retardant compositions to teeth|
|US3696811 *||17 juin 1971||10 oct. 1972||Squibb & Sons Inc||Periodontal bandage and backing therefor|
|US3769071 *||4 juin 1971||30 oct. 1973||Minnesota Mining & Mfg||Pressure sensitive adhesive tape comprising 5-fluorouracil|
|US3960150 *||15 sept. 1975||1 juin 1976||Alza Corporation||Bioerodible ocular device|
|US3981303 *||31 juil. 1975||21 sept. 1976||Alza Corporation||Bioerodible ocular device|
|US3986510 *||1 août 1975||19 oct. 1976||Alza Corporation||Bioerodible ocular device|
|US3993071 *||24 juil. 1975||23 nov. 1976||Alza Corporation||Bioerodible ocular device|
|US3993073 *||3 mars 1975||23 nov. 1976||Alza Corporation||Novel drug delivery device|
|US3996934 *||9 août 1971||14 déc. 1976||Alza Corporation||Medical bandage|
|US3998215 *||23 avr. 1971||21 déc. 1976||Minnesota Mining And Manufacturing Company||Bio-medical electrode conductive gel pads|
|US4022203 *||22 janv. 1976||10 mai 1977||Win Ackley||Treated patch for minor cuts|
|US4062361 *||7 juil. 1975||13 déc. 1977||Coloplast International A/S||Bilaminar ostomy sealing disc|
|US4239488 *||15 juin 1979||16 déc. 1980||Sempler Vance A||Encapsulated denture adhesive and method of use|
|US4253460 *||27 juil. 1979||3 mars 1981||E. R. Squibb & Sons, Inc.||Ostomy adhesive|
|US4265233 *||6 avr. 1979||5 mai 1981||Unitika Ltd.||Material for wound healing|
|US4292299 *||7 juil. 1980||29 sept. 1981||Teijin Limited||Slow-releasing medical preparation to be administered by adhering to a wet mucous surface|
|US4306551 *||28 juil. 1980||22 déc. 1981||Lectec Corporation||Sterile improved bandage and sealant|
|US4307717 *||28 juil. 1980||29 déc. 1981||Lectec Corporation||Sterile improved bandage containing a medicament|
|US4321252 *||17 déc. 1980||23 mars 1982||Key Pharmaceuticals, Inc.||Polymeric diffusion matrix containing ester derivatives of estradiol|
|US4329333 *||24 nov. 1980||11 mai 1982||Arthur Barr||Method for the oral treatment of dogs and other animals|
|US4460562 *||30 mars 1983||17 juil. 1984||Key Pharmaceuticals, Inc.||Polymeric diffusion matrix containing propranolol|
|US4470962 *||28 avr. 1981||11 sept. 1984||Key Pharmaceuticals, Inc.||Polymeric diffusion matrix|
|US4492685 *||30 janv. 1984||8 janv. 1985||Key Pharmaceuticals, Inc.||Protective skin matrix|
|US4631227 *||5 déc. 1983||23 déc. 1986||Kenji Nakamura||Toilet article|
|US4655211 *||8 août 1985||7 avr. 1987||Unitika Ltd.||Hemostatic agent|
|US4695465 *||5 avr. 1985||22 sept. 1987||Takeda Chemical Industry, Ltd.||Soft patch|
|US4728323 *||24 juil. 1986||1 mars 1988||Minnesota Mining And Manufacturing Company||Antimicrobial wound dressings|
|US4877618 *||18 mars 1988||31 oct. 1989||Reed Jr Fred D||Transdermal drug delivery device|
|US4906475 *||16 févr. 1988||6 mars 1990||Paco Pharmaceutical Services||Estradiol transdermal delivery system|
|US4984570 *||14 sept. 1989||15 janv. 1991||Karl Otto Braun Kg||Knitted hydrophobic web wound dressing|
|US4991574 *||15 août 1990||12 févr. 1991||Dow Corning Corporation||Surgical dressing|
|US5096715 *||20 nov. 1989||17 mars 1992||Alko Ltd.||Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist|
|US5207652 *||23 oct. 1991||4 mai 1993||Bioderm||Medical apparatus fixation and infection control device|
|US5234957 *||23 déc. 1991||10 août 1993||Noven Pharmaceuticals, Inc.||Compositions and methods for topical administration of pharmaceutically active agents|
|US5332576 *||21 mai 1993||26 juil. 1994||Noven Pharmaceuticals, Inc.||Compositions and methods for topical administration of pharmaceutically active agents|
|US5336501 *||29 avr. 1992||9 août 1994||Lohmann Gmbh & Co. Kg||Cross-linked hydrogels and their use as wound dressings|
|US5437621 *||12 janv. 1993||1 août 1995||Marmon Holdings, Inc.||Medical dressing of a multilayered material|
|US5446070 *||27 août 1993||29 août 1995||Nover Pharmaceuticals, Inc.||Compositions and methods for topical administration of pharmaceutically active agents|
|US5480377 *||28 févr. 1994||2 janv. 1996||New Dimensions In Medicine, Inc.||Wound dressing having a roll configuration|
|US5536263 *||30 mars 1994||16 juil. 1996||Lectec Corporation||Non-occulusive adhesive patch for applying medication to the skin|
|US5741510 *||8 avr. 1996||21 avr. 1998||Lectec Corporation||Adhesive patch for applying analgesic medication to the skin|
|US5829442 *||12 juin 1996||3 nov. 1998||Medical Concepts Development, Inc.||Antimicrobial containing solventless hot melt adhesive composition|
|US6016862 *||10 mars 1999||25 janv. 2000||Hormel Foods Corporation||Collagen or gelatin crumble composition and uses|
|US6090915 *||18 oct. 1996||18 juil. 2000||Hormel Foods Corporation||Collagen or gelatin crumble composition and uses|
|US6096333 *||8 oct. 1997||1 août 2000||Lectec Corporation||Method of forming adhesive patch for applying medication to the skin|
|US6096334 *||14 déc. 1998||1 août 2000||Lectec Corporation||Adhesive patch for applying medication to the skin and method|
|US6469227||12 mai 2000||22 oct. 2002||Lectec Corporation||Antipruritic patch|
|US6607746||24 juil. 2002||19 août 2003||Medical Concepts Development, Inc.||Antimicrobial containing solventless hot melt adhesive composition|
|US6664309||7 déc. 2000||16 déc. 2003||Bostik Findley, Inc.||Antimicrobial hot melt adhesive|
|US7087269||22 juin 2001||8 août 2006||Lg Chemical Co., Ltd.||Multi-component composite membrane and method for preparing the same|
|US7157614||21 déc. 2001||2 janv. 2007||Fountainhead, Llc||Treatment devices providing targeted antimicrobial action|
|US7357891||30 janv. 2004||15 avr. 2008||Monosol Rx, Llc||Process for making an ingestible film|
|US7425292||14 févr. 2002||16 sept. 2008||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US7666337||28 mai 2004||23 févr. 2010||Monosol Rx, Llc||Polyethylene oxide-based films and drug delivery systems made therefrom|
|US7824588||14 avr. 2008||2 nov. 2010||Monosol Rx, Llc||Method of making self-supporting therapeutic active-containing film|
|US7910641||14 déc. 2006||22 mars 2011||Monosol Rx, Llc||PH modulated films for delivery of actives|
|US7972618||20 sept. 2007||5 juil. 2011||Monosol Rx, Llc||Edible water-soluble film containing a foam reducing flavoring agent|
|US8017150||22 avr. 2008||13 sept. 2011||Monosol Rx, Llc||Polyethylene oxide-based films and drug delivery systems made therefrom|
|US8475832||7 août 2009||2 juil. 2013||Rb Pharmaceuticals Limited||Sublingual and buccal film compositions|
|US8603514||10 juil. 2007||10 déc. 2013||Monosol Rx, Llc||Uniform films for rapid dissolve dosage form incorporating taste-masking compositions|
|US8614179||17 juil. 2009||24 déc. 2013||E-Therapeutics Plc||Antibacterial combination therapy for the treatment of gram positive bacterial infections|
|US8652378||29 mars 2013||18 févr. 2014||Monosol Rx Llc||Uniform films for rapid dissolve dosage form incorporating taste-masking compositions|
|US8663687||13 mai 2010||4 mars 2014||Monosol Rx, Llc||Film compositions for delivery of actives|
|US8685437||26 mars 2009||1 avr. 2014||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US8765167||8 sept. 2006||1 juil. 2014||Monosol Rx, Llc||Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions|
|US8900497||23 août 2013||2 déc. 2014||Monosol Rx, Llc||Process for making a film having a substantially uniform distribution of components|
|US8900498||23 août 2013||2 déc. 2014||Monosol Rx, Llc||Process for manufacturing a resulting multi-layer pharmaceutical film|
|US8906277||23 août 2013||9 déc. 2014||Monosol Rx, Llc||Process for manufacturing a resulting pharmaceutical film|
|US8974826||10 juin 2011||10 mars 2015||Monosol Rx, Llc||Nanoparticle film delivery systems|
|US9108340||23 août 2013||18 août 2015||Monosol Rx, Llc||Process for manufacturing a resulting multi-layer pharmaceutical film|
|US9248050||11 oct. 2012||2 févr. 2016||Roar Consultants||Wound dressing garment|
|US20030107149 *||14 févr. 2002||12 juin 2003||International Fluidics.||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20040234605 *||19 nov. 2003||25 nov. 2004||Cox David D.||Antimicrobial adhesive system|
|US20040258738 *||8 juil. 2004||23 déc. 2004||Kania Bruce G.||Treatment devices providing targeted antimicrobial action|
|US20040258896 *||30 janv. 2004||23 déc. 2004||Monosolrx Llc.||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20050184427 *||29 mars 2005||25 août 2005||Monosolrx, Llc.||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20060039958 *||28 sept. 2005||23 févr. 2006||Monosolrx, Llc.||Multi-layer films having uniform content|
|US20060147493 *||22 juil. 2003||6 juil. 2006||Yang Robert K||Packaging and dispensing of rapid dissolve dosage form|
|US20070069416 *||22 juin 2006||29 mars 2007||Monosolrx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20070122455 *||8 sept. 2006||31 mai 2007||Monosolrx, Llc.||Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions|
|US20070149731 *||14 déc. 2006||28 juin 2007||Monosolrx, Llc.||PH modulated films for delivery of actives|
|US20070154527 *||5 déc. 2006||5 juil. 2007||Monosoirx, Llc||Topical film compositions for delivery of actives|
|US20070172515 *||19 janv. 2007||26 juil. 2007||Monosolrx, Llc||Film bandage for mucosal administration of actives|
|US20070190157 *||19 janv. 2007||16 août 2007||Monosoirx, Llc.||Film lined packaging and method of making same|
|US20070281003 *||13 févr. 2007||6 déc. 2007||Fuisz Richard C||Polymer-Based Films and Drug Delivery Systems Made Therefrom|
|US20080044454 *||10 juil. 2007||21 févr. 2008||Monosolrx Llc||Uniform films for rapid dissolve dosage form incorporating taste-masking compositions|
|US20080075825 *||20 sept. 2007||27 mars 2008||Fuisz Richard C||Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent|
|US20080078413 *||22 mai 2007||3 avr. 2008||Padget David B||Surgical drape|
|US20080081071 *||28 sept. 2007||3 avr. 2008||Pradeep Sanghvi||Film Embedded Packaging and Method of Making Same|
|US20080220067 *||7 janv. 2008||11 sept. 2008||Cox David D||Antimicrobial adhesive system|
|US20080260805 *||14 avr. 2008||23 oct. 2008||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20080260809 *||22 avr. 2008||23 oct. 2008||Monosol Rx, Llc||Polyethylene oxide-based films and drug delivery systems made therefrom|
|US20090005443 *||20 juin 2008||1 janv. 2009||Malcolm Philip Young||Treatment of Depression|
|US20090181069 *||26 mars 2009||16 juil. 2009||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20100021526 *||7 oct. 2009||28 janv. 2010||Monosol Rx, Llc||Ph modulated films for delivery of actives|
|US20100227937 *||26 févr. 2010||9 sept. 2010||Cox David D||Antimicrobial adhesive system|
|US20110020217 *||10 oct. 2008||27 janv. 2011||E-Therapeutics Plc||Treatment of melanoma|
|US20110033376 *||4 juil. 2008||10 févr. 2011||Malcolm Philip Young||Treatment of Melanoma|
|US20110033541 *||7 août 2009||10 févr. 2011||Monosol Rx, Llc||Sublingual and buccal film compositions|
|US20110033542 *||7 août 2009||10 févr. 2011||Monosol Rx, Llc||Sublingual and buccal film compositions|
|US20110039906 *||18 juil. 2008||17 févr. 2011||E-Therapeutics Plc||Antibacterial combination therapy|
|US20110212173 *||17 juin 2009||1 sept. 2011||e-Therapeutics Ple||Controlled Release Treatment of Depression|
|EP0044624A1 *||23 juin 1981||27 janv. 1982||E.R. Squibb & Sons, Inc.||Lyophilized hydrocolloid foam|
|EP0159168A2 *||4 avr. 1985||23 oct. 1985||Takeda Chemical Industries, Ltd.||Soft patch drug preparation|
|EP0159168A3 *||4 avr. 1985||8 janv. 1986||Takeda Chemical Industries, Ltd.||Soft patch drug preparation|
|EP0161681A2 *||15 mai 1985||21 nov. 1985||Mitsubishi Acetate Co., Ltd.||Gel plate and process for preparing same|
|EP0161681A3 *||15 mai 1985||29 avr. 1987||Mitsubishi Acetate Co., Ltd.||Gel plate and process for preparing same|
|EP0167263A1 *||28 mai 1985||8 janv. 1986||Matrix Pharmaceutical Inc.||Drug-containing matrices for introduction into cellular lesion areas|
|EP0177920A3 *||7 oct. 1985||3 juin 1987||Teijin Limited||Pharmaceutical composition for external use containing active type vitam d3|
|EP0232580A2 *||21 août 1986||19 août 1987||Alza Corporation||Transdermal system II|
|EP0232580A3 *||21 août 1986||21 juin 1989||Alza Corporation||Transdermal system ii|
|EP0297828A1 *||28 juin 1988||4 janv. 1989||The Kendall Company||Novel medicated dressings|
|EP0438749A1 *||20 déc. 1990||31 juil. 1991||Beiersdorf Aktiengesellschaft||Self-adhesive mass from gelatine|
|EP0666081A1 *||20 janv. 1995||9 août 1995||Bristol-Myers Squibb Company||Wound dressing|
|EP0852148A1||7 janv. 1997||8 juil. 1998||Israel Fiber Institute||Products having anti-microbial activity|
|EP2014282A2||20 juin 2008||14 janv. 2009||E-Therapeutics plc||Treatment of depression|
|EP2508231A2||15 nov. 2007||10 oct. 2012||E-Therapeutics Plc||Imidazoles for treating multi-drug resistant bacterial infections|
|EP2529733A1||18 juil. 2008||5 déc. 2012||E-Therapeutics Plc||Antibacterial combination therapy|
|EP2529737A1||18 juil. 2008||5 déc. 2012||E-Therapeutics plc||Antibacterial combination therapy|
|WO1993007928A1 *||23 oct. 1992||29 avr. 1993||Bioderm, Inc.||Medical apparatus fixation and infection control device|
|WO2009013480A2||18 juil. 2008||29 janv. 2009||E-Therapeutics Plc||Antibacterial combination therapy|
|WO2011030106A1||10 sept. 2010||17 mars 2011||E-Therapeutics Plc||Cancer cell apoptosis|
|WO2012046006A2||7 oct. 2011||12 avr. 2012||University Of Dundee||Cancer targets|
|WO2012104589A1||2 févr. 2012||9 août 2012||University Of Edinburgh||Weight related disorders|
|WO2013160645A1||26 avr. 2013||31 oct. 2013||E-Therapeutics Plc||Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg|
|WO2013164561A1||3 mai 2013||7 nov. 2013||E-Therapeutics Plc||Tramadol for treating depression|
|WO2015067746A1||7 nov. 2014||14 mai 2015||Bsn Medical Gmbh||Medical dressing|
|WO2017068349A1||20 oct. 2016||27 avr. 2017||E-Therapeutics Plc||Cannabinoid for use in immunotherapy|
|Classification aux États-Unis||604/304, 602/49, 433/180, 602/50|
|Classification internationale||A61K9/00, A61F13/00, A61F13/15, A61L15/58, A61L15/44|
|Classification coopérative||A61F2013/00659, A61K9/006, A61L15/44, A61F2013/00472, A61F2013/53445, A61F13/122, A61L15/585, A61F13/0236, A61F13/8405, A61L2300/00, A61F13/00063|
|Classification européenne||A61L15/58M, A61K9/00M18D, A61L15/44, A61F13/00|